What this means in practice
Do not take St John's Wort with imatinib. The label response to a strong CYP3A inducer is usually a dose increase, but that is a decision for the treating haematologist or oncologist with monitoring, not something to arrange around a supplement.
What people say
A herbal mood support that fits alongside a long-term cancer tablet, because herbal and pharmaceutical are treated as separate categories that do not touch.
What the evidence supports
In 12 healthy volunteers, two weeks of St John's Wort raised imatinib clearance by 43% and cut total exposure by 30%, with half-life falling from 12.8 to 9.0 hours (Frye 2004); an independent group published the same finding in the same year. Reduced imatinib levels are listed among the documented St John's Wort interactions in the review literature (Borrelli 2009). Neither study measured disease control, so the clinical consequence is inferred from imatinib being a drug whose effect tracks blood level.
How it is supposed to work
Imatinib is cleared predominantly by CYP3A4, and hyperforin increases that enzyme. The drug is removed faster, so less of each dose is present over the day.
Which way it runs
One-directional. St John's Wort speeds up imatinib clearance; imatinib does not affect the herb. Imatinib is a daily tablet taken at home for years, which is what makes an at-home supplement decision able to reach it at all.
What is still missing
Separating herbal from pharmaceutical is a category the liver does not recognise. The enzyme that clears imatinib does not check where a molecule was bought, and a third of the daily dose goes missing either way.
Sources
- Effect of St John's wort on imatinib mesylate pharmacokineticsFrye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ, 2004
- Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observationsBorrelli F, Izzo AA, 2009